Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy
The introduction of immune checkpoint inhibitors (ICI) instigated significant improvement in the management of metastatic NSCLC. Currently, metastatic NSCLC remains in the category of ‘incurable’ malignancies and there is no biologic or mechanistic basis to guide the duration of treatment with immun...
Guardado en:
Autores principales: | Hunter C Cochran, Yadav Pandey, Richard W. Nicholas, Eric J. Del Giacco, A. Mazin Safar |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca44d3c5070c4ceea8cf2379ae04ca66 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021) -
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021) -
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Rilan Bai, et al.
Publicado: (2021) -
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)